APPROVAL WITH CONDITIONS OF PrEXJADE* (deferasirox) 125 MG, 250 MG, - Management of thalassemia - Document - PDFSEARCH.IO

First Page	Meta Content
	APPROVAL WITH CONDITIONS OF PrEXJADE* (deferasirox) 125 MG, 250 MG, & 500 MG DISPERSIBLE TABLETS FOR ORAL SUSPENSION FOR USE IN THE MANAGEMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIAS AGED Add to Reading List Document Date: 2013-07-12 14:25:45 Open Document File Size: 153,68 KB Share Result on Facebook Country Canada / / MedicalCondition sore throat / chronic iron / indigestion / acute cardiac failure / headache / myelodysplastic syndromes / sleep disorder / nausea / bloating / fever / pain / vomiting / severe rash / sickle cell disease / diarrhea / thalassemia / dizziness / transfusiondependent anemias / constipation / tiredness / hearing loss / rash / gastrointestinal disorders / anemia / / MedicalTreatment chelation therapy / oral therapy / chelation therapies / blood transfusions / / / Position pharmacist / / Product EXJADE / MG DISPERSIBLE TABLETS FOR ORAL SUSPENSION / Desferal / / URL http / SocialTag Antidotes Chelating agents Anemias Deferasirox Triazoles Thalassemia Myelodysplastic syndrome Chelation therapy Iron overload Medicine

APPROVAL WITH CONDITIONS OF PrEXJADE* (deferasirox) 125 MG, 250 MG, & 500 MG DISPERSIBLE TABLETS FOR ORAL SUSPENSION FOR USE IN THE MANAGEMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIAS AGED Add to Reading List